|1.||Gallick, Gary E: 9 articles (09/2014 - 12/2003)|
|2.||Jove, Richard: 7 articles (02/2014 - 10/2005)|
|3.||Lee, Francis Y: 7 articles (02/2010 - 10/2005)|
|4.||Li, Shaoguang: 6 articles (01/2008 - 05/2004)|
|5.||Lowell, Clifford A: 5 articles (09/2015 - 09/2008)|
|6.||Johnson, Faye M: 5 articles (11/2012 - 01/2007)|
|7.||Sakai, Ryuichi: 5 articles (11/2011 - 11/2003)|
|8.||Cheng, Heung-Chin: 4 articles (03/2015 - 01/2011)|
|9.||Araujo, John C: 4 articles (09/2014 - 05/2008)|
|10.||Tanaka, Masamitsu: 4 articles (01/2013 - 07/2005)|
09/01/2007 - "Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors."
07/01/2000 - "These findings suggest that PP1 and other inhibitors specific for Src family kinases are potentially useful for the treatment of Ras-associated cancers."
04/30/2015 - "Here, we study the role of Src kinases in the Drosophila intestinal stem cell (ISC) lineage, during tissue homeostasis and tumor onset. "
05/02/2014 - "Therefore, most physiological studies regarding Csk function have been focused on Csk as a negative regulator of Src family tyrosine kinases and as a potential tumor suppressor. "
12/15/2007 - "As the use of Src family inhibitors in clinical trials on solid tumors is in its infancy, further studies on the roles of Src family kinases in tumor progression, chemoresistance, epidermal-to-mesenchymal transition, and other properties of tumor progression will be important in designing the most effective clinical trials using these inhibitors."
01/01/2015 - "Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells."
12/01/2008 - "New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression."
05/14/2004 - "Conversely, inhibition of Src family tyrosine kinases by the pyrazolopyrimidine PP2, as in kinase-inactive Hck mutants, significantly reduces IL-6-triggered activation of extracellular signal-regulated kinase and AKT-1, leading to significant reduction of multiple myeloma cell proliferation and survival. "
01/01/2014 - "The multikinase inhibitor dasatinib blocks the constitutive activation of oncogenic Src kinases in multiple myeloma (MM) cells and potentially enhances natural killer (NK) cell activity. "
03/15/2002 - "In multiple myeloma, IL-6 only enhanced the proliferation of CD45+ tumor cells that harbored the IL-6-independent activation of src family kinases even though STAT3 and ERK1/2 could be activated in response to IL-6 in both CD45+ and CD45(minus sign) cells. "
04/01/2005 - "This study examines the role of Src kinases in Flt3 signaling and the oncogenic effects of leukemia-associated Flt3 mutations. "
11/07/2006 - "Besides BCR-ABL and SRC kinases, stem cell pathways must be targeted for curative therapy of Ph(+) leukemia."
04/01/2005 - "Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations."
01/01/2003 - "This review focuses on our current understanding of the deregulation and role of Src family kinases in human cancer and leukemia. "
01/01/2003 - "SRC family kinases: potential targets for the treatment of human cancer and leukemia."
|4.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/01/2011 - "Their availability permits real-time activity measurement of aberrantly activated oncogenic Src kinases in the crude lysate of chronic myelogenous leukemia cells. "
05/01/2004 - "Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia."
02/01/2015 - "Flow cytometric monitoring of the in vitro inhibition of the phosphorylation of CRKL and of SRC family kinases in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors."
07/01/2007 - "Complementary inhibition of tyrosine and SRC kinases implement dual SRC/ABL inhibitor effects in chronic myeloid leukemia (CML). "
12/01/2006 - "Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib."
04/01/2005 - "The participation of Src kinases in the induction of BCR-ABL-induced B cell acute lymphoblastic leukaemia (B-ALL), but not chronic myeloid leukaemia (CML), demonstrates cell type-specific signalling in Philadelphia chromosome-positive (Ph+) leukaemias. "
08/01/2015 - "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by BCR/ABL and SRC family tyrosine kinases. "
11/01/2012 - "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by constitutively activated BCR-ABL and SRC family tyrosine kinases.They"
01/01/2008 - "Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia."
01/01/2007 - "Retained activation of Src kinases by the BCR-ABL oncoprotein in leukaemic cells following inhibition of BCR-ABL kinase activity by imatinib indicates that Src activation by BCR-ABL is independent of BCR-ABL kinase activity and provides an explanation for reduced effectiveness of the BCR-ABL kinase activity inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukaemia. "
|1.||dasatinib (BMS 354825)
|3.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||DNA (Deoxyribonucleic Acid)
|5.||epidermal growth factor receptor VIII
|6.||erlotinib (CP 358,774)
|7.||glucuronyl glucosamine glycan sulfate (Vessel)
|9.||Azacitidine (5 Azacytidine)
|2.||Heterologous Transplantation (Xenotransplantation)